Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2023 | Using multimodal artificial intelligence models in the STAMPEDE trials

Charles Parker • 22 Oct 2023
ESMO 2023
Genitourinary Cancer Prostate Cancer
STAMPEDE

Charles Parker, MBBS, UCL Cancer Institute, London, UK, comments on the use of multimodal artificial intelligence (MMAI)-derived models in the STAMPEDE trials (NCT00268476), which assessed androgen deprivation therapy in patients with high-risk localized/metastatic prostate cancer. Using biopsy samples, certain clinical variables were associated with a positive prognosis, enabling future stratification of patients. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Charles Parker

The future of artificial intelligence in prostate cancer
0:48
The future of artificial intelligence in prostate cancer
Charles Parker • 22 Oct 2023
Multimodal artificial intelligence models in prostate cancer
1:45
Multimodal artificial intelligence models in prostate cancer
Charles Parker • 22 Oct 2023

Related Videos

Current and emerging systemic strategies in biochemically relapsed prostate cancer
2:45
Current and emerging systemic strategies in biochemically relapsed prostate cancer
Ashwin Sachdeva • 16 May 2026
How has SABR improved radiotherapy practice in kidney cancer?
1:06
How has SABR improved radiotherapy practice in kidney cancer?
Shankar Siva • 16 May 2026
Which patients with kidney cancer may benefit from SABR treatment?
1:58
Which patients with kidney cancer may benefit from SABR treatment?
Shankar Siva • 16 May 2026
Management of brain metastasis in patients with poor-risk testicular cancer
1:03
Management of brain metastasis in patients with poor-risk testicular cancer
Darren Feldman • 30 May 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals